Form 4: Jasper Therapeutics Director Vishal Kapoor Granted Power of Attorney, Acquires Stock Options

Vishal Kapoor, a director at Jasper Therapeutics, granted power of attorney and acquired 7,500 stock options on June 6, 2024.

Summary

• Vishal Kapoor, a director of Jasper Therapeutics, Inc., has granted power of attorney to Ronald Martell and Herb Cross to execute and file SEC Forms 3, 4, 5, and 144 on his behalf.
• This power of attorney covers transactions related to Section 16(a) of the Securities Exchange Act of 1934 and Rule 144 under the Securities Act of 1933.
• Kapoor also acquired 7,500 stock options on June 6, 2024, exercisable from June 6, 2025, to June 6, 2034, at a price of $25.41 per share.

Sentiment

Score: 7

Explanation: The document reflects standard corporate governance procedures and executive compensation practices, indicating a neutral to slightly positive sentiment.

Positives

• The granting of power of attorney simplifies the process of SEC filings for Vishal Kapoor.
• The acquisition of stock options aligns Kapoor's interests with those of the company's shareholders.

Industry Context

This is a standard practice for corporate directors to delegate SEC filing responsibilities and receive stock-based compensation.

Comparison to Industry Standards

• Power of attorney arrangements are common among corporate executives to streamline administrative tasks related to SEC filings.
• Stock option grants are a typical component of executive compensation packages in the biotechnology industry, aligning management's interests with shareholder value creation.
• The vesting schedule and exercise price of the options appear to be within typical ranges for similar companies.

Stakeholder Impact

• The granting of stock options to a director can align their interests with those of shareholders, potentially driving long-term value creation.

Key Dates